• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PTEN 癌基因 Y68 框移突变是子宫内膜癌细胞系对多西紫杉醇耐药的机制。

Oncogenic Y68 frame shift mutation of PTEN represents a mechanism of docetaxel resistance in endometrial cancer cell lines.

机构信息

Department of Prosthodontics Dentistry, Hospital of Stomatology, Jilin University, Changchun, China.

NHC Key Laboratory of Radiobiology, Jilin University, Changchun, China.

出版信息

Sci Rep. 2019 Feb 14;9(1):2111. doi: 10.1038/s41598-019-38585-9.

DOI:10.1038/s41598-019-38585-9
PMID:30765787
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6375989/
Abstract

In this study, we aimed to identify mutations of key genes associated with docetaxel resistance in nine endometrial cancer cell lines. Endometrial cancers are associated with several critical gene mutations, including PIK3A, PTEN, and KRAS. Different gene mutations in endometrial cancer cells have varied responses to anticancer drugs and cancer therapies. The most frequently altered gene in endometrioid endometrial carcinoma tumors is PTEN. PTEN protein has lipid phosphatase and protein phosphatase activity, as well as other functions in the nucleus. Although the tumor-suppressive function of PTEN has mainly been attributed to its lipid phosphatase activity, a role for PTEN protein phosphatase activity in cell cycle regulation has also been suggested. Various tumor type-specific PTEN mutations are well documented. Here, nine endometrioid endometrial cancer cell lines with PIK3A, PTEN, and KRAS gene mutations were treated with docetaxel and radiation. One mutation with a docetaxel drug-resistant effect was a truncated form of PTEN. Among PTEN mutations in endometrial cancer cells, the Y68 frame shift mutation of PTEN constitutes a major mechanism of resistance to docetaxel treatment. The molecular mechanism involves truncation of the 403 amino acid PTEN protein at amino acid 68 by the Y68 frame shift, leading to the loss of PTEN protein phosphatase and lipid phosphatase activities.

摘要

在这项研究中,我们旨在确定与 9 种子宫内膜癌细胞系中多西紫杉醇耐药相关的关键基因的突变。子宫内膜癌与几种关键基因突变有关,包括 PIK3A、PTEN 和 KRAS。子宫内膜癌细胞中的不同基因突变对抗癌药物和癌症治疗有不同的反应。在子宫内膜样腺癌肿瘤中最常改变的基因是 PTEN。PTEN 蛋白具有脂质磷酸酶和蛋白磷酸酶活性,以及核内的其他功能。尽管 PTEN 的肿瘤抑制功能主要归因于其脂质磷酸酶活性,但也有人提出 PTEN 蛋白磷酸酶活性在细胞周期调控中的作用。已经充分记录了各种肿瘤类型特异性的 PTEN 突变。在这里,用多西紫杉醇和辐射处理了 9 种具有 PIK3A、PTEN 和 KRAS 基因突变的子宫内膜样癌细胞系。一种具有多西紫杉醇耐药作用的突变是 PTEN 的截断形式。在子宫内膜癌细胞中的 PTEN 突变中,PTEN 的 Y68 移码突变构成了对多西紫杉醇治疗耐药的主要机制。分子机制涉及由 Y68 移码导致的 403 个氨基酸的 PTEN 蛋白在第 68 位截断,导致 PTEN 蛋白磷酸酶和脂质磷酸酶活性丧失。

相似文献

1
Oncogenic Y68 frame shift mutation of PTEN represents a mechanism of docetaxel resistance in endometrial cancer cell lines.PTEN 癌基因 Y68 框移突变是子宫内膜癌细胞系对多西紫杉醇耐药的机制。
Sci Rep. 2019 Feb 14;9(1):2111. doi: 10.1038/s41598-019-38585-9.
2
Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.抑制 PI3K-AKT-mTOR 通路可使子宫内膜癌细胞系对 PARP 抑制剂敏感。
BMC Cancer. 2017 Sep 8;17(1):638. doi: 10.1186/s12885-017-3639-0.
3
Phosphatase and Tensin Homolog Is a Potential Target for Ovarian Cancer Sensitization to Cytotoxic Agents.磷酸酶与张力蛋白同源物是使卵巢癌对细胞毒性药物敏感的潜在靶点。
Int J Gynecol Cancer. 2016 May;26(4):632-9. doi: 10.1097/IGC.0000000000000657.
4
PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.PTEN 缺失使子宫内膜样子宫内膜癌对联合 PARP-PI3K 抑制敏感,但对 PARP 抑制作为单药治疗不敏感。
Oncogene. 2018 Jan 18;37(3):341-351. doi: 10.1038/onc.2017.326. Epub 2017 Sep 25.
5
High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.对原发性子宫内膜癌中的 PIK3CA、PTEN、KRAS、FBXW7 和 TP53 突变进行高通量检测。
Gynecol Oncol. 2013 Feb;128(2):327-34. doi: 10.1016/j.ygyno.2012.11.037. Epub 2012 Dec 4.
6
Effect of microRNA-29b on proliferation, migration, and invasion of endometrial cancer cells.微小RNA-29b对子宫内膜癌细胞增殖、迁移和侵袭的影响。
J Int Med Res. 2019 Aug;47(8):3803-3817. doi: 10.1177/0300060519844403. Epub 2019 Jun 12.
7
Consequences of the loss of p53, RB1, and PTEN: relationship to gefitinib resistance in endometrial cancer.p53、RB1和PTEN缺失的后果:与子宫内膜癌吉非替尼耐药性的关系
Gynecol Oncol. 2007 Jul;106(1):94-104. doi: 10.1016/j.ygyno.2007.03.006. Epub 2007 May 8.
8
PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.PTEN 缺失预测子宫内膜样腺癌对 PARP 抑制剂的敏感性。
Sci Transl Med. 2010 Oct 13;2(53):53ra75. doi: 10.1126/scitranslmed.3001538.
9
PTEN mutations do not cause nuclear beta-catenin accumulation in endometrial carcinomas.PTEN突变不会导致子宫内膜癌中β-连环蛋白在细胞核内积聚。
Hum Pathol. 2004 Oct;35(10):1260-5. doi: 10.1016/j.humpath.2004.06.007.
10
Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27.子宫内膜癌中PTEN表达的改变与细胞周期蛋白依赖性激酶抑制剂p27的下调有关。
Histopathology. 2002 Nov;41(5):437-45. doi: 10.1046/j.1365-2559.2002.01455.x.

引用本文的文献

1
Progress of estrogen receptor and spliceosome in endometrial carcinoma.雌激素受体与剪接体在子宫内膜癌中的研究进展
Front Endocrinol (Lausanne). 2025 Aug 25;16:1586191. doi: 10.3389/fendo.2025.1586191. eCollection 2025.
2
The Histomorphology to Molecular Transition: Exploring the Genomic Landscape of Poorly Differentiated Epithelial Endometrial Cancers.从组织形态学到分子转变:探索低分化子宫内膜上皮癌的基因组格局
Cells. 2025 Mar 5;14(5):382. doi: 10.3390/cells14050382.
3
Landscape of Endometrial Cancer: Molecular Mechanisms, Biomarkers, and Target Therapy.

本文引用的文献

1
(S034) Pilot Phase II Trial of "Sandwich" Radiation and Combination Carboplatin and Paclitaxel Chemotherapy in Patients With High-Risk Endometrial Cancer.(S034)高危子宫内膜癌患者“三明治”放疗联合卡铂和紫杉醇化疗的II期试点试验
Oncology (Williston Park). 2015 Apr 21;29(4 Suppl 1).
2
PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-α/VEGF pathway in endometrial cancer.PI3K/mTOR通路抑制通过抑制子宫内膜癌中的HIF1-α/VEGF通路克服放射抗性。
Gynecol Oncol. 2015 Jul;138(1):174-80. doi: 10.1016/j.ygyno.2015.04.015. Epub 2015 Apr 22.
3
Sequential chemotherapy and radiotherapy in the sandwich method for advanced endometrial cancer: a meta-analysis.
子宫内膜癌全景:分子机制、生物标志物与靶向治疗
Cancers (Basel). 2024 May 27;16(11):2027. doi: 10.3390/cancers16112027.
4
A Review: Genetic Mutations as a Key to Unlocking Drug Resistance in Cervical Cancer.综述:基因突变是揭示宫颈癌耐药性的关键。
Cancer Control. 2024 Jan-Dec;31:10732748241261539. doi: 10.1177/10732748241261539.
5
TPD52 as a Potential Prognostic Biomarker and its Correlation with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma: Bioinformatic Analysis and Experimental Verification.TPD52作为子宫体子宫内膜癌潜在的预后生物标志物及其与免疫浸润的相关性:生物信息学分析与实验验证
Recent Pat Anticancer Drug Discov. 2025;20(1):71-88. doi: 10.2174/0115748928267447231107101539.
6
Pten knockout affects drug resistance differently in melanoma and kidney cancer.PTEN 敲除对黑色素瘤和肾癌的耐药性有不同的影响。
Pharmacol Rep. 2023 Oct;75(5):1187-1199. doi: 10.1007/s43440-023-00523-y. Epub 2023 Sep 6.
7
PTEN mutations as predictive marker for the high-grade endometrial cancer development in slovak women.PTEN 突变作为斯洛伐克女性高级别子宫内膜癌发展的预测标志物。
Physiol Res. 2022 Dec 27;71(Suppl 1):S125-S135. doi: 10.33549/physiolres.935030.
8
COVID-19-associated lncRNAs as predictors of survival in uterine corpus endometrial carcinoma: A prognostic model.新冠病毒相关长链非编码RNA作为子宫体子宫内膜癌生存预测指标:一种预后模型
Front Genet. 2022 Sep 6;13:986453. doi: 10.3389/fgene.2022.986453. eCollection 2022.
9
The top 100 most cited papers on endometrial carcinoma: A bibliometric analysis.子宫内膜癌领域被引用次数最多的100篇论文:文献计量分析。
Front Oncol. 2022 Aug 18;12:987980. doi: 10.3389/fonc.2022.987980. eCollection 2022.
10
The functional roles of the circRNA/Wnt axis in cancer.环状 RNA/Wnt 轴在癌症中的功能作用。
Mol Cancer. 2022 May 5;21(1):108. doi: 10.1186/s12943-022-01582-0.
晚期子宫内膜癌三明治法序贯化疗与放疗的荟萃分析
Medicine (Baltimore). 2015 Apr;94(16):e672. doi: 10.1097/MD.0000000000000672.
4
Signalling pathways in endometrial cancer.子宫内膜癌中的信号通路。
Contemp Oncol (Pozn). 2014;18(3):143-8. doi: 10.5114/wo.2014.43154. Epub 2014 Jun 18.
5
Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.PI3K/PTEN/Akt/mTOR信号通路在人类癌症治疗中的当前临床调控
J Cancer Res Clin Oncol. 2015 Apr;141(4):671-89. doi: 10.1007/s00432-014-1803-3. Epub 2014 Aug 22.
6
The benefit of adjuvant chemotherapy combined with postoperative radiotherapy for endometrial cancer: a meta-analysis.辅助化疗联合术后放疗治疗子宫内膜癌的疗效:一项荟萃分析。
Eur J Obstet Gynecol Reprod Biol. 2013 Sep;170(1):39-44. doi: 10.1016/j.ejogrb.2013.06.009. Epub 2013 Jun 26.
7
PI3K pathway dependencies in endometrioid endometrial cancer cell lines.PI3K 通路依赖性在子宫内膜样癌细胞系中的研究。
Clin Cancer Res. 2013 Jul 1;19(13):3533-44. doi: 10.1158/1078-0432.CCR-12-3815. Epub 2013 May 14.
8
Integrated genomic characterization of endometrial carcinoma.子宫内膜癌的综合基因组特征分析。
Nature. 2013 May 2;497(7447):67-73. doi: 10.1038/nature12113.
9
Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.成纤维细胞生长因子受体抑制剂多韦替尼(TKI258)和 NVP-BGJ398 在人子宫内膜癌细胞中的活性。
Mol Cancer Ther. 2013 May;12(5):632-42. doi: 10.1158/1535-7163.MCT-12-0999. Epub 2013 Feb 26.
10
The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.PI3K/AKT/mTOR 通路作为子宫内膜癌的治疗靶点。
Clin Cancer Res. 2012 Nov 1;18(21):5856-64. doi: 10.1158/1078-0432.CCR-12-0662. Epub 2012 Oct 18.